- Total sales reached $16.3 billion, up 5% year over year
- Animal Health sales grew 13% to $1.8 billion
- GAAP EPS was a loss of $1.72, impacted by a $3.62/share acquisition charge
- Non-GAAP EPS was a loss of $1.28
- Full-year 2026 sales outlook raised to $65.8–$67.0 billion
Merck & Co. reported first-quarter 2026 worldwide sales of $16.3 billion, representing 5% growth compared to the prior year, with strength in both its pharmaceutical and animal health segments.
Animal Health delivered $1.8 billion in revenue, increasing 13% year over year, with growth across both livestock and companion animal portfolios.
Despite revenue gains, profitability was significantly impacted by a one-time acquisition-related charge tied to Cidara Therapeutics. As a result, the company reported a GAAP net loss of $4.2 billion and a GAAP loss per share of $1.72. On an adjusted basis, non-GAAP loss per share was $1.28.
Looking ahead, Merck raised its full-year 2026 revenue guidance to a range of $65.8 billion to $67.0 billion and expects non-GAAP EPS between $5.04 and $5.16, excluding the impact of additional business development transactions.
Information sourced from company press release.
